RT Journal Article
SR Electronic
T1 Neoadjuvant Chemotherapy with Divided-dose Docetaxel, Cisplatin and Fluorouracil for Patients with Squamous Cell Carcinoma of the Esophagus
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 829
OP 834
VO 36
IS 2
A1 OJIMA, TOSHIYASU
A1 NAKAMORI, MIKIHITO
A1 NAKAMURA, MASAKI
A1 KATSUDA, MASAHIRO
A1 HAYATA, KEIJI
A1 KATO, TOMOYA
A1 KITADANI, JUNYA
A1 TABATA, HIROTAKA
A1 TAKEUCHI, AKIHIRO
A1 IWAHASHI, MAKOTO
A1 YAMAUE, HIROKI
YR 2016
UL http://ar.iiarjournals.org/content/36/2/829.abstract
AB Background: The aim of this phase II study was to evaluate the feasibility of a neoadjuvant chemotherapy regimen consisting of divided-dose docetaxel and cisplatin, with 5-fluorouracil (NAC-DCF), for treatment of patients with stage II/III squamous cell carcinoma of the esophagus (SCCE). Patients and Methods: The NAC-DCF regimen, consisting of 2-h infusion of docetaxel at 35 mg/m2 on days 1 and 8, 4-h infusion of cisplatin at 12 mg/m2 on days 1-5, and continuous infusion of 5-fluorouracil at 600 mg/m2 on days 1-5, was administered. We compared NAC-DCF with conventional NAC-CF. Results: The DCF group comprised of 45 patients, and the CF group comprised of 28 patients. The incidence of grade 3/4 neutropenia was significantly higher in the DCF group (56%) than in the CF group (0%). Grade 2/3 pathological response was attained in a significantly higher percentage of patients in the DCF group (40%) than in the CF group (11%) (p=0.0153). Conclusion: This DCF regimen led to a high frequency of pathological responses among patients with advanced SCCE.